Demographics, Treatment Regimens and the Use of Angiotensin-receptor Blockers in Heart Failure: Findings from the Valsartan Heart Failure Trial

Author： Majahalme S  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.31, Iss.5, 2003-09, pp. : 351-361

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure

By McKelvie Robert S  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 3, 2004-03 ,pp. : 245-253

Informa Healthcare

Access to resources Recommend Favorite

Valsartan for the treatment of heart failure

By Latini Roberto   Masson Serge   Staszewsky Lidia   Maggioni Aldo P  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 1, 2004-01 ,pp. : 181-193

Informa Healthcare

Access to resources Recommend Favorite

The use of -blockers, ACE inhibitors/ angiotensin receptor blockers (ARBs), or a combination of both, is associated with decreased mortality among elderly inpatients with congestive heart failure

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 437, 2003-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Valsartan: In Chronic Heart Failure

By Wellington K.   Goa K.L.  

American Journal of Cardiovascular Drugs, Vol. 2, Iss. 4, 2002-01 ,pp. : 267-274

Adis International

Access to resources Recommend Favorite

Optimising the Use of -Blockers in Older Patients with Heart Failure

By Owen A.  

Drugs & Aging, Vol. 19, Iss. 9, 2002-01 ,pp. : 671-684

Adis International

Access to resources Recommend Favorite